Literature DB >> 32335701

Long-term treatment response to PD-1 blockade therapy in a patient with DLBCL relapsed after anti-CD19 chimeric antigen receptor T cell treatment.

Lu Zhang1, Wei Zhang1, Daobin Zhou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32335701     DOI： 10.1007/s00277-020-03993-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  1 in total

1.  Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.

Authors:  Rui Zhang; Qi Deng; Yan-Yu Jiang; Hai-Bo Zhu; Jia Wang; Ming-Feng Zhao
Journal:  Oncol Rep       Date:  2019-04-03       Impact factor: 3.906
  1 in total
  2 in total

1.  Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report.

Authors:  Cang-Jian Zhang; Jun-Yu Zhang; Lin-Jie Li; Neng-Wen Xu
Journal:  World J Clin Cases       Date:  2022-07-26       Impact factor: 1.534

Review 2.  Emerging Novel Combined CAR-T Cell Therapies.

Authors:  Anh Nguyen; Gary Johanning; Yihui Shi
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.